Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Jun-30-16 |
| 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 8-K |
Revenues: |
BetterHelp | 1,019.6 | 721.2 | 345.1 | | | | | |
Teladoc Health Integrated Care | 1,373.9 | 1,300.9 | 744.3 | | | | | |
Other | 13.3 | 10.6 | 180.2 | | | | | |
Total revenues | 2,406.8 | 2,032.7 | 1,094.0 | 553.3 | 417.9 | 233.3 | 123.2 | 53.4 |
Revenue growth [+] | 18.4% | 85.8% | 97.7% | 32.4% | 79.1% | 89.4% | 59.2% | 53.5% |
BetterHelp | 41.4% | 109.0% | | | | | | |
Teladoc Health Integrated Care | 5.6% | 74.8% | | | | | | |
Other | 25.5% | -94.1% | | | | | | |
Cost of goods sold | 744.0 | 650.3 | 390.8 | 184.5 | 128.7 | 61.6 | 32.0 | 14.8 |
Gross profit | 1,662.9 | 1,382.4 | 703.1 | 368.8 | 289.2 | 171.7 | 91.2 | 38.5 |
Gross margin | 69.1% | 68.0% | 64.3% | 66.7% | 69.2% | 73.6% | 74.0% | 72.2% |
Selling, general and administrative [+] | 1,300.6 | 1,105.3 | 886.9 | 449.3 | 261.2 | 175.4 | 109.5 | 50.2 |
Sales and marketing | 850.7 | 667.3 | 380.2 | | 144.3 | 95.6 | 61.0 | 27.0 |
General and administrative | 449.9 | 438.0 | 506.7 | | 116.9 | 79.8 | 48.6 | 23.2 |
Research and development | 333.6 | 311.9 | 164.9 | | 54.4 | 34.5 | 21.8 | 10.1 |
Other operating expenses | 7.4 | | | | 8.9 | 18.1 | 3.2 | 4.4 |
EBITDA [+] | 21.2 | -34.7 | -348.7 | -41.5 | -35.3 | -56.3 | -43.3 | -26.1 |
EBITDA growth | -161.1% | -90.0% | 740.4% | 17.7% | -37.4% | 30.0% | 4.4% | -3.4% |
EBITDA margin | 0.9% | -1.7% | -31.9% | -7.5% | -8.4% | -24.1% | -35.2% | -48.9% |
Depreciation | 11.4 | 8.9 | 4.8 | 3.4 | 4.1 | 3.8 | 2.2 | 3.1 |
EBITA | 9.8 | -43.7 | -353.5 | -44.8 | -39.4 | -60.1 | -45.5 | -29.2 |
EBITA margin | 0.4% | -2.1% | -32.3% | -8.1% | -9.4% | -25.8% | -36.9% | -54.7% |
Amortization of intangibles | 244.6 | 195.3 | 64.7 | 35.6 | 31.5 | 15.3 | 6.1 | |
EBIT [+] | -234.8 | -239.0 | -418.2 | -80.4 | -70.9 | -75.4 | -51.6 | -29.2 |
EBIT growth | -1.8% | -42.9% | 419.9% | 13.5% | -6.0% | 46.1% | 11.3% | 1.2% |
EBIT margin | -9.8% | -11.8% | -38.2% | -14.5% | -17.0% | -32.3% | -41.9% | -54.7% |
Non-recurring items [+] | 13,418.4 | 26.6 | 88.2 | | | | 11.1 | |
Asset impairment | 13,402.8 | | | | | | | |
Restructuring charges | 15.6 | 26.6 | 88.2 | | | | 7.0 | |
Legal settlement | | | | | | | 4.1 | |
Interest expense | 9.3 | 80.4 | 60.0 | | 26.1 | 17.5 | 2.6 | 0.8 |
Interest expense | 9.3 | 80.4 | 60.0 | | 26.1 | 17.5 | 2.6 | 0.8 |
Other income (expense), net [+] | -0.9 | -38.7 | -9.6 | -29.0 | | -14.1 | -8.5 | |
Acquisition-related costs | | | | | 10.4 | 13.2 | | |
Gain (loss) on sale of assets | | | | | -5.5 | | | |
Gain (loss) on debt retirement | | -43.7 | -9.1 | | | | | |
Other | -0.9 | 5.1 | -0.5 | | | | | |
Pre-tax income | -13,663.3 | -384.7 | -576.0 | -109.5 | -97.0 | -107.0 | -73.7 | -30.0 |
Income taxes | -3.8 | 44.1 | -90.9 | -10.6 | 0.1 | -0.2 | 0.5 | 0.2 |
Tax rate | 0.0% | | 15.8% | 9.7% | | 0.2% | | |
Net income | -13,659.5 | -428.8 | -485.1 | 0.0 | -97.1 | -106.8 | -74.2 | -30.2 |
Net margin | -567.5% | -21.1% | -44.3% | 0.0% | -23.2% | -45.8% | -60.3% | -56.5% |
|
Basic EPS [+] | ($84.60) | ($2.73) | ($5.36) | $0.00 | ($1.47) | ($1.93) | ($1.75) | ($0.78) |
Growth | 2996.4% | -49.0% | | -100.0% | -23.5% | 9.9% | -39.8% | -94.1% |
Diluted EPS [+] | ($84.60) | ($2.73) | ($5.36) | $0.00 | ($1.47) | ($1.93) | ($1.75) | ($0.78) |
Growth | 2996.4% | -49.0% | | -100.0% | -23.5% | 9.9% | -39.8% | -94.1% |
|
Shares outstanding (basic) [+] | 161.5 | 156.9 | 90.5 | 71.8 | 65.8 | 55.4 | 42.3 | 38.7 |
Growth | 2.9% | 73.4% | 26.0% | 9.1% | 18.8% | 30.9% | 112.5% | 1605.0% |
Shares outstanding (diluted) [+] | 161.5 | 156.9 | 90.5 | 71.8 | 65.8 | 55.4 | 42.3 | 38.7 |
Growth | 2.9% | 73.4% | 26.0% | 9.1% | 18.8% | 30.9% | 112.5% | 1605.0% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|